Carglumic acid Drug Asset Due Diligence Report 2026

This Carglumic acid Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Carglumic acid can convert its Small molecule drug profile and CPS1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Carglumic acid (query alias: carglumic acid)
Modality / target	Small molecule drug; CPS1; CPS1 activators
Highest global status	Approved
Originator	Pola Chemical Industries, Inc.
Active developers	Eurocept International B.V., Recordati Rare Diseases, Recordati Rare Diseases, Inc.

The MCP disease footprint includes Acidemia, Isovaleric, Methylmalonic Acidemia, N-Acetyl Glutamate Synthetase Deficiency. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20242574	Phase 4	进行中（招募完成）	15	Not disclosed
CTR20211274	Not Applicable	已完成	90	Not disclosed
NCT05040178	Not Applicable	Recruiting	20	Effects of Carbaglu® on plasma ammonia levels

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Real-World Experience of Carglumic Acid for Methylmalonic and Propionic Acidurias: An Interim Analysis of the Multicentre Observational PROTECT Study.

Not Applicable; n=10; evaluation: not stated. Reported fields: Peak ammonia level = 250 µmol/L

Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial

Phase 3; n=38; evaluation: Superior. Reported fields: Hyperammonemia(the number of emergency room (ER) admissions) = 12.76 Event ; Hyperammonemia(the number of emergency room (ER) admissions) = 6.31 Event

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

Phase 2; n=35; evaluation: not stated. Reported fields: -; Time to the Primary Outcome (Earlier of Ammonia <50 µmol/L or Hospital Discharge) = 1.37 Hazard Ratio (95% Confidence Interval, 0.88 - 2.13); Time to the Primary Outcome (Earlier of Ammonia <50 µmol/L or Hospital Discharge) = 0.79 Hazard Ratio (95% Confidence Interval, 0.22 - 2.81)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Carglumic acid addresses Acidemia, Isovaleric, Methylmalonic Acidemia, N-Acetyl Glutamate Synthetase Deficiency. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CPS1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Homogenously splittable tablet compositions comprising carglumic acid”. The milestone feed surfaced a patent-application signal described as “Pharmaceutical formulation for carglumic acid”. The milestone feed surfaced a patent-application signal described as “Improved process for the preparation of carglumic acid”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO